Latest Articles

  • Vitamin D: A metabolic bone disease perspective
    Bruce Long, MD, FACR, BS Pharm
    Cleveland Clinic Journal of Medicine February 2023, 90 (2) 91-92; DOI: https://doi.org/10.3949/ccjm.90a.22086

    When checking levels, clinicians should keep in mind that vitamin D levels fluctuate by season and time of day, and that different laboratories may use different assays that yield different results.

  • What are the treatment options for myasthenia gravis if first-line agents fail?
    Christopher Zust, MD and John A. Morren, MD
    Cleveland Clinic Journal of Medicine February 2023, 90 (2) 81-84; DOI: https://doi.org/10.3949/ccjm.90a.22022

    From 5% to 20% of patients may have a suboptimal response or prohibitive adverse effects over a period of a few weeks to 3 months.

  • The constellation of vitamin D, the acute-phase response, and inflammation
    Maria J. Antonelli, MD, Irving Kushner, MD and Murray Epstein, MD, FASN, FACP
    Cleveland Clinic Journal of Medicine February 2023, 90 (2) 85-89; DOI: https://doi.org/10.3949/ccjm.90a.22048

    An astronomic increase in vitamin D testing and supplementation is happening in the absence of an evidence-based rationale.

  • Some complexities of diabetes and the heart
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 13-14; DOI: https://doi.org/10.3949/ccjm.90b.01023

    Patients with diabetes are at greater risk of coronary artery disease than their peers without diabetes. That’s straight and simple. But there the simplicity ends.

  • Bone turnover markers to monitor oral bisphosphonate therapy
    Nikita Ashcherkin, MD, Archna A. Patel, MD, MPH, Alicia Algeciras-Schimnich, PhD and Krupa B. Doshi, MD, FACE
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 26-31; DOI: https://doi.org/10.3949/ccjm.90a.22002

    Rapid changes in levels of bone turnover markers can be useful in monitoring the effectiveness of therapy and improving adherence to therapy.

  • Update in cutaneous manifestations of COVID-19: Special populations
    Update in cutaneous manifestations of COVID-19: Special populations
    Samantha Polly, MD, Inga M. Muser, MD and Anthony P. Fernandez, MD, PhD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 43-52; DOI: https://doi.org/10.3949/ccjm.90a.22013

    Recognition of skin reactions and their implications is beneficial to clinicians in shaping patient counseling and anticipatory guidance. An illustrated guide.

  • Statins may increase diabetes, but benefit still outweighs risk
    Byron J. Hoogwerf, MD, FACP, FACE
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 53-62; DOI: https://doi.org/10.3949/ccjm.90a.22069

    The weight of the evidence suggests that statin use is associated with an increased risk of new-onset diabetes mellitus, but the magnitude of the effect has varied across studies.

  • Which patients hospitalized with alcohol withdrawal syndrome should receive high-dose parenteral thiamine?
    Rahul B. Ganatra, MD, MPH, Anthony C. Breu, MD and Matthew V. Ronan, MD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 22-25; DOI: https://doi.org/10.3949/ccjm.90a.22026

    The authors briefly outline risk factors for Wernicke encephalopathy and when high-dose parenteral thiamine is indicated.

  • Making best use of bone turnover markers to monitor oral bisphosphonate therapy
    Sarah Keller, MD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 32-34; DOI: https://doi.org/10.3949/ccjm.90a.22092

    Clinical applications of bone turnover markers can include determining when to start or end a bisphosphonate “holiday” and measuring treatment response.

  • Median rhomboid glossitis caused by tongue-brushing
    Tatsuya Shindo, MD
    Cleveland Clinic Journal of Medicine January 2023, 90 (1) 15-16; DOI: https://doi.org/10.3949/ccjm.90a.21111

    The patient had started vigorous brushing 1 month earlier after being told that she had bad breath.

Pages